Impact of human leukocyte antigen matching and recipients' panel reactive antibodies on two-year outcome in presensitized renal allograft recipients

Chinese Medical Journal

Volumn 122, Issue 4, 2009, Pages 420-426

  Meng, Hui Lin ^a   Jin, Xun Bo ^a   Li, Xiang Tie ^b   Wang, Hong Wei ^a   Lü, Jia Ju ^a  

^a SHANDONG UNIVERSITY   (China)

^b JINAN MILITARY GENERAL HOSPITAL   (China)

Author keywords

Donor specific antibody; HLA antigens; Kidney transplantation; Panel reactive antibody; Sensitization

Indexed keywords

CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PANEL REACTIVE ANTIBODY; PREDNISOLONE; TACROLIMUS; ALLOANTIBODY; HLA ANTIGEN;

ADULT; ALLOIMMUNITY; ARTICLE; CADAVER; CONTROLLED STUDY; FEMALE; GRAFT RECIPIENT; GRAFT SURVIVAL; HLA MATCHING; HUMAN; IMMUNOADSORPTION; KIDNEY ALLOGRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PLASMAPHERESIS; POLYMERASE CHAIN REACTION; POSTOPERATIVE PERIOD; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; ALLOTRANSPLANTATION; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; GRAFT REJECTION; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; MIDDLE AGED; MORTALITY; TREATMENT OUTCOME;

ADULT; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 65649139955     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2009.04.0012     Document Type: Article

References (39)

1. Hardy S, Lee SH, Terasaki PI. Sensitization 2001. Clin Transpl 2001; 15: 271-278.
2. McCune TR, Thacker LR 2nd, Blanton JW, Adams PL. Sensitized patients require sharing of highly matched kidneys. Transplantation 2002; 73: 1891-1896.
3. Cecka JM, Terasaki PI. The UNOS scientific renal transplant registry. United Network for Organ Sharing. Clin Transpl 1995; 9: 1-18.
4. Wolf JS, Callender CO, Terasaki PI, Cecka JM, Gjertson DW, Takemoto SK. How should cadaver-donor kidneys be allocated in the United States. Clin Transpl 1995; 9: 351-361.
5. Starzl TE, Eliasziw M, Gjertson D, Terasaki PI, Fung JJ, Trucco M, et al. HLA and cross-reactive antigen group matching for cadaver kidney allocation. Transplantation 1997; 64: 983-991.
6. Tan J, Tang X, Xie T. HLA-amino acid residue matching standard and immunogenic response. Natl Med J China (Chin) 1999; 79: 810-813.
7. Susal C, Opelz G. Kidney graft failure and presensization against HLA I class and class II antigens. Transplantation 2002; 73: 1269-1273.
8. Goes N, Chandraker A. Human leukocyte antigen matching in renal transplantation: an update. Curr Opin Nephrol Hypertens 2000; 9: 683-687.
9. Schnitzler MA, Hollenbeak CS, Cohen DS, Woodward RS, Lowell JA, Singer GG, et al. The economic implications of HLA matching in cadaveric renal transplantation. N Engl J Med 1999; 341: 1440-1446.
10. Hwang AH, Cho YW, Cicciarelli J, Mentser M, Iwaki Y, Hardy BE. Risk factors for short- and long-term survival of primary cadaveric renal allografts in pediatric recipients: a UNOS analysis. Transplantation 2005; 80: 466-470.
11. Morris PJ, Johnson RJ, Fuggle SV, Belger MA, Briggs JD. Analysis of factors that affect outcome of primary cadaveric renal transplantation in the UK. HLA Task Force of the Kidney Advisory Group of the United Kingdom Transplant Support Service Authority (UKTSSA). Lancet 1999; 354: 1147-1152.
12. Marsh SG, Albert ED, Bodmer WF, Bontrop RE, Dupont B, Erlich HA, et al. Nomenclature for factors of the HLA system, 2002. Hum Immunol 2002; 63: 1213-1268.
13. Hwang SH, Oh HB, Shin ES, Yew M, Kim SC, Han DJ. Influence of mismatching of HLA cross-reactive groups on cadaveric kidney transplantation. Transplant Proc 2005; 37: 4194-4198.
14. Lazda VA, Mozes MF. An evaluation of HLA cross-reactive group matching on graft survival in deceased donor kidney recipients. Transplant Proc 2005; 37: 661-663.
15. Laux G, Opelz G. Immunological relevance of CREG matching in cadaver kidney transplantation. Transplantation 2004; 78: 442-446.
16. Crowe DO. The effect of cross-reactive epitope group matching on allocation and sensitization. Clin Transplant 2003; 17: 13-16.
17. Egfjord M, Jakobsen BK, Ladefoged J. No impact of cross-reactive group human leucocyte antigen class I matching on long-term kidney graft survival. Scand J Immunol 2003; 57: 362-365.
18. Stobbe I, van der Meer-Prins EM, de Lange P, Oudshoorn M, De Meester J, Doxiadis II, et al. Cross-reactive group matching does not lead to a better allocation and survival of donor kidneys. Transplantation 2000; 70: 157-161.
19. Opelz G, Wujciak T, Döhler B, Scherer S, Mytilineos J. HLA compatibility and organ transplant survival. Rev Immnogenenet 1999; 1: 334-342.
20. Susal C, Opelz G. Good kidney transplant outcome in recipients with presensitization against HLA class II but not HLA class I. Hum Immunol 2004; 65: 810-816.
21. Barama A, Oza U, Panek R, Belitsky P, MacDonald AS, Lawen J, et al. Effect of recipient sensitization (peak PRA) on graft outcome in haploidentical living related kidney transplants. Clin Transpl 2000; 14: 212-217.
22. Singh D, Kiberd BA, West KA, Kamal K, Balbontin F, Belitsky P, et al. Importance of peak PRA inpredicting the kidney transplant survival in highly sensitized patients. Transplant Proc 2003; 35: 2395-2397.
23. Gloor J. Kidney transplantation in the hyperimmunized patient. Contrib Nephrol 2005; 146: 11-21.
24. Feucht HE, Schneeberger H, Hillebrand G, Burkhardt K, Weiss M, Riethmüller G, et al. Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int 1993; 43: 1333-1338.
25. Worthington JE, McEwen A, McWilliam LJ, Picton ML, Martin S. Association between C4d staining in renal transplant biopsies, production of donor-specific HLA antibodies, and graft outcome. Transplantation 2007; 83: 398-403.
26. Howie AJ. The association among C4d staining in renal transplant biopsies, the production of donor-specific HLA antibodies, and graft outcome. Transplantation 2007; 83: 373-374.
27. Halloran PF, Wadgymar A, Ritchie S, Falk J, Solez K, Srinivasa NS. The significance of the anti-class I antibody response. I. Clinical and pathologic features of anti-class I-mediated rejection. Transplantation 1990; 49: 85-91.
28. Halloran PF, Schlaut J, Solez K, Srinivasa NS. The significance of the anti-class I response. II. Clinical and pathologic features of renal transplants with anti-class I-like antibody. Transplantation 1992; 53: 550-555.
29. Ben-Youssef R, Iwaki Y, Baron P, Franco E, Rowsell E, Buckert L, et al. Successful living related kidney transplantation across an anti-donor HLA antibody. Transplant Proc 2006; 38: 1280-1282.
30. Pollinger HS, Stegall MD, Gloor JM, Moore SB, Degoey SR, Ploeger NA, et al. Kidney transplantation in patients with antibodies against donor HLA class II. Am J Transplant 2007; 7: 857-863.
31. Ghasemian SR, Light JA, Currier CB, Sasaki T, Aquino A, Rees J, et al. The significance of the IgG anti-B-cell crossmatch on renal transplant outcome. Clin Transpl 1997; 11: 485-487.
32. Ghasemian SR, Light JA, Sasaki TA, Barhyte DY. Hyperacute rejection from antibody against class II HLA antigens. Clin Transpl 1998; 12: 569-571.
33. Muczynski KA, Cotner T, Anderson SK. Unusual expression of human lymphocyte antigen class II in normal renal microvascular endothelium. Kidney Int 2001; 59: 488-497.
34. Muczynski KA, Ekle DM, Coder DM, Anderson SK. Normal human kidney HLA-DR-expressing renal microvascular endothelial cells: characterization, isolation, and regulation of MHC class II expression. J Am Soc Nephrol 2003; 14: 1336-1348.
35. Stegall MD, Gloor J, Winters JL, Moore SB, Degoey S. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006; 6: 346-351.
36. Zachary AA, Montgomery RA, Leffell MS. Factors associated with and predictive of persistence of donor-specific antibody after treatment with plasmapheresis and intravenous immunoglobulin. Hum Immunol 2005; 66: 364-370.
37. Haas M, Böhmig GA, Leko-Mohr Z, Exner M, Regele H, Derfler K, et al. Peri-operative immunoadsorption in sensitized renal transplant recipients. Nephrol Dial Transplant 2002; 17: 1503-1508.
38. Hickstein H, Korten G, Bast R, Barz D, Nizze H, Schmidt R. Immunoadsorption of sensitized kidney transplant candidates immediately prior to surgery. Clin Transpl 2002; 16: 97-101.
39. Wang D, Wu WZ, Yang SL, Chen JH, Tan JM. Preoperative single-bolus high-dose antithymocyte globulin as induction therapy in sensitized renal transplant recipients. Chin Med J 2006; 119: 1683-1688.